Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

745 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma.
Sivakumar S, Lucas FAS, McDowell TL, Lang W, Xu L, Fujimoto J, Zhang J, Futreal PA, Fukuoka J, Yatabe Y, Dubinett SM, Spira AE, Fowler J, Hawk ET, Wistuba II, Scheet P, Kadara H. Sivakumar S, et al. Among authors: yatabe y. Cancer Res. 2017 Nov 15;77(22):6119-6130. doi: 10.1158/0008-5472.CAN-17-1605. Epub 2017 Sep 26. Cancer Res. 2017. PMID: 28951454 Free PMC article.
Genomic landscape of allelic imbalance in premalignant atypical adenomatous hyperplasias of the lung.
Sivakumar S, San Lucas FA, Jakubek YA, McDowell TL, Lang W, Kallsen N, Peyton S, Davies GE, Fukuoka J, Yatabe Y, Zhang J, Futreal PA, Fowler J, Fujimoto J, Ehli EA, Hawk ET, Wistuba II, Kadara H, Scheet P. Sivakumar S, et al. Among authors: yatabe y. EBioMedicine. 2019 Apr;42:296-303. doi: 10.1016/j.ebiom.2019.03.020. Epub 2019 Mar 21. EBioMedicine. 2019. PMID: 30905849 Free PMC article.
SRGN-Triggered Aggressive and Immunosuppressive Phenotype in a Subset of TTF-1-Negative Lung Adenocarcinomas.
Tanaka I, Dayde D, Tai MC, Mori H, Solis LM, Tripathi SC, Fahrmann JF, Unver N, Parhy G, Jain R, Parra ER, Murakami Y, Aguilar-Bonavides C, Mino B, Celiktas M, Dhillon D, Casabar JP, Nakatochi M, Stingo F, Baladandayuthapani V, Wang H, Katayama H, Dennison JB, Lorenzi PL, Do KA, Fujimoto J, Behrens C, Ostrin EJ, Rodriguez-Canales J, Hase T, Fukui T, Kajino T, Kato S, Yatabe Y, Hosoda W, Kawaguchi K, Yokoi K, Chen-Yoshikawa TF, Hasegawa Y, Gazdar AF, Wistuba II, Hanash S, Taguchi A. Tanaka I, et al. Among authors: yatabe y. J Natl Cancer Inst. 2022 Feb 7;114(2):290-301. doi: 10.1093/jnci/djab183. J Natl Cancer Inst. 2022. PMID: 34524427 Free PMC article.
HNF4α as a marker for invasive mucinous adenocarcinoma of the lung.
Sugano M, Nagasaka T, Sasaki E, Murakami Y, Hosoda W, Hida T, Mitsudomi T, Yatabe Y. Sugano M, et al. Among authors: yatabe y. Am J Surg Pathol. 2013 Feb;37(2):211-8. doi: 10.1097/PAS.0b013e31826be303. Am J Surg Pathol. 2013. PMID: 23108025
Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer.
French JD, Johnatty SE, Lu Y, Beesley J, Gao B, Kalimutho M, Henderson MJ, Russell AJ, Kar S, Chen X, Hillman KM, Kaufmann S, Sivakumaran H, O'Reilly M, Wang C, Korbie DJ; Australian Ovarian Cancer Study Group; Australian Ovarian Cancer Study; Lambrechts D, Despierre E, Van Nieuwenhuysen E, Lambrechts S, Vergote I, Karlan B, Lester J, Orsulic S, Walsh C, Fasching PA, Beckmann MW, Ekici AB, Hein A, Matsuo K, Hosono S, Pisterer J, Hillemanns P, Nakanishi T, Yatabe Y, Goodman MT, Lurie G, Matsuno RK, Thompson PJ, Pejovic T, Bean Y, Heitz F, Harter P, du Bois A, Schwaab I, Hogdall E, Kjaer SK, Jensen A, Hogdall C, Lundvall L, Engelholm SA, Brown B, Flanagan JM, Metcalf MD, Siddiqui N, Sellers T, Fridley B, Cunningham J, Schildkraut JM, Iversen E, Weber RP, Brennan D, Berchuck A, Pharoah P, Harnett P, Norris MD, Haber M, Goode EL, Lee JS, Khanna KK, Meyer KB, Chenevix-Trench G, deFazio A, Edwards SL, MacGregor S; Ovarian Cancer Association Consortium. French JD, et al. Among authors: yatabe y. Oncotarget. 2016 Feb 9;7(6):6353-68. doi: 10.18632/oncotarget.7047. Oncotarget. 2016. PMID: 26840454 Free PMC article.
A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer.
Soh SX, Siddiqui FJ, Allen JC, Kim GW, Lee JC, Yatabe Y, Soda M, Mano H, Soo RA, Chin TM, Ebi H, Yano S, Matsuo K, Niu X, Lu S, Isobe K, Lee JH, Yang JC, Zhao M, Zhou C, Lee JK, Lee SH, Lee JY, Ahn MJ, Tan TJ, Tan DS, Tan EH, Ong ST, Lim WT. Soh SX, et al. Among authors: yatabe y. Oncotarget. 2017 Jun 20;8(25):41474-41486. doi: 10.18632/oncotarget.17102. Oncotarget. 2017. PMID: 28467813 Free PMC article. Review.
745 results